HRGN (Harvard Apparatus Regenerative Technology) Piotroski F-Score: 4 (As of Jun. 27, 2026) — 33% Above Median


HRGN Harvard Apparatus Regenerative Technology Inc HRGN
33 GF Score
Price $1.39
GF Value $5.34
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Harvard Apparatus Regenerative Technology Piotroski F-Score?

Harvard Apparatus Regenerative Technology HRGN 33 Piotroski F-Score is 4 as of Jun. 27, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates HRGN with a GF Score™ of 33/100 and a GF Value™ of $5.34 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,911 Consumer Packaged Goods companies, Harvard Apparatus Regenerative Technology ranks worse than 66.93% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Harvard Apparatus Regenerative Technology has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Harvard Apparatus Regenerative Technology's Piotroski F-Score or its related term are showing as below:

HRGN' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 4

During the past 13 years, the highest Piotroski F-Score of Harvard Apparatus Regenerative Technology was 4. The lowest was 1. And the median was 3.

Harvard Apparatus Regenerative Technology  (OTCPK:HRGN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Harvard Apparatus Regenerative Technology Piotroski F-Score Related Terms


Harvard Apparatus Regenerative Technology Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Harvard Apparatus Regenerative Technology's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Apparatus Regenerative Technology Piotroski F-Score Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 4.00 4.00 4.00 3.00

Harvard Apparatus Regenerative Technology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 4.00 3.00 4.00

HRGN vs DTEAF, WYGC, BFNH: Piotroski F-Score Comparison

For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Apparatus Regenerative Technology Piotroski F-Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's Piotroski F-Score falls into.


HRGN
33GF Score
Harvard Apparatus Regenerative Technology Inc HRGN
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -1.823 + -1.7 + -1.687 + -1.601 = $-6.81 Mil.
Cash Flow from Operations was -0.941 + -1.465 + -0.664 + -0.937 = $-4.01 Mil.
Revenue was 0.317 + 0.123 + 0.219 + 0.226 = $0.89 Mil.
Gross Profit was 0.015 + 0.011 + 0.02 + 0.02 = $0.07 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3.415 + 2.137 + 2.546 + 2.677 + 1.798) / 5 = $2.5146 Mil.
Total Assets at the begining of this year (Mar25) was $3.42 Mil.
Long-Term Debt & Capital Lease Obligation was $0.06 Mil.
Total Current Assets was $0.87 Mil.
Total Current Liabilities was $1.65 Mil.
Net Income was -2.498 + -1.86 + -1.344 + -1.659 = $-7.36 Mil.

Revenue was 0.056 + 0.059 + 0.258 + 0.045 = $0.42 Mil.
Gross Profit was 0.043 + -0.011 + 0.083 + 0.012 = $0.13 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(2.415 + 1.73 + 5.311 + 4.442 + 3.415) / 5 = $3.4626 Mil.
Total Assets at the begining of last year (Mar24) was $2.42 Mil.
Long-Term Debt & Capital Lease Obligation was $0.17 Mil.
Total Current Assets was $2.30 Mil.
Total Current Liabilities was $1.20 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Harvard Apparatus Regenerative Technology's current Net Income (TTM) was -6.81. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Harvard Apparatus Regenerative Technology's current Cash Flow from Operations (TTM) was -4.01. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-6.811/3.415
=-1.99443631

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-7.361/2.415
=-3.04803313

Harvard Apparatus Regenerative Technology's return on assets of this year was -1.99443631. Harvard Apparatus Regenerative Technology's return on assets of last year was -3.04803313. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Harvard Apparatus Regenerative Technology's current Net Income (TTM) was -6.81. Harvard Apparatus Regenerative Technology's current Cash Flow from Operations (TTM) was -4.01. ==> -4.01 > -6.81 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.055/2.5146
=0.02187227

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0.172/3.4626
=0.04967366

Harvard Apparatus Regenerative Technology's gearing of this year was 0.02187227. Harvard Apparatus Regenerative Technology's gearing of last year was 0.04967366. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=0.873/1.651
=0.52877044

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=2.302/1.195
=1.92635983

Harvard Apparatus Regenerative Technology's current ratio of this year was 0.52877044. Harvard Apparatus Regenerative Technology's current ratio of last year was 1.92635983. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Harvard Apparatus Regenerative Technology's number of shares in issue this year was 17.581. Harvard Apparatus Regenerative Technology's number of shares in issue last year was 15.919. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.066/0.885
=0.07457627

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.127/0.418
=0.30382775

Harvard Apparatus Regenerative Technology's gross margin of this year was 0.07457627. Harvard Apparatus Regenerative Technology's gross margin of last year was 0.30382775. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0.885/3.415
=0.25915081

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0.418/2.415
=0.17308489

Harvard Apparatus Regenerative Technology's asset turnover of this year was 0.25915081. Harvard Apparatus Regenerative Technology's asset turnover of last year was 0.17308489. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Harvard Apparatus Regenerative Technology has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Harvard Apparatus Regenerative Technology (HRGN) has a Piotroski F-Score of 4 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Harvard Apparatus Regenerative Technology and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, Harvard Apparatus Regenerative Technology's Piotroski F-Score has ranged from 1.00 to 4.00. According to the industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1279 out of 1911 companies in the Consumer Packaged Goods industry, placing it in the top 66.9%.
Is Harvard Apparatus Regenerative Technology's Piotroski F-Score too high?
Harvard Apparatus Regenerative Technology's current Piotroski F-Score of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. The Consumer Packaged Goods industry median Piotroski F-Score is 5.00. Harvard Apparatus Regenerative Technology's value of 4 is 20% below this industry median. Based on the distribution chart, Harvard Apparatus Regenerative Technology ranks #1279 out of 1911 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's Piotroski F-Score compare to DTEAF and WYGC?
According to the Consumer Packaged Goods industry distribution chart, Harvard Apparatus Regenerative Technology ranks #1279 out of 1911 companies for Piotroski F-Score. This places Harvard Apparatus Regenerative Technology in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Harvard Apparatus Regenerative Technology's value of 4 is 20% below this benchmark. Historically, Harvard Apparatus Regenerative Technology's own Piotroski F-Score has ranged from 1.00 to 4.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Harvard Apparatus Regenerative Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Consumer Packaged Goods company?
The median Piotroski F-Score among Consumer Packaged Goods companies is 5.00, based on 1,911 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Apparatus Regenerative Technology's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Harvard Apparatus Regenerative Technology and its competitors. For the Consumer Packaged Goods industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Apparatus Regenerative Technology's current Piotroski F-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology (HRGN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.34, compared to a current price of $1.39 — trading 74% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% above median its 10-year median of 3.00 and 20% below the Consumer Packaged Goods industry median of 5.00. Harvard Apparatus Regenerative Technology's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current Piotroski F-Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Apparatus Regenerative Technology (HRGN) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology stock appears to be undervalued. The current stock price of $1.39 is trading 74% below its estimated GF Value™ of $5.34. GuruFocus considers Harvard Apparatus Regenerative Technology to be Possible Value Trap.

Key valuation signals for HRGN:

  • Piotroski F-Score: 4 (33% above median its 10-year median of 3.00)
  • GF Value™: $5.34 vs. price of $1.39 (74% below fair value)
  • GF Score™: 33/100 with 2 warning signs
  • Industry Position: 20% below the Consumer Packaged Goods median (#1279 of 1911)

No single metric tells the full story. See the HRGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harvard Apparatus Regenerative Technology Business Description

Address 84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
33GF Score

Get the complete analysis for HRGN

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$5.34
GF Value